Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with @entity12350 in XXXX with Newly Diagnosed @entity6 .

@entity1 @entity6 @entity12350 @entity164 @entity413
To identify a new regimen to optimize treatment for @entity1 with newly diagnosed @entity164 2 @entity6 (T2DM) by short-term continuous subcutaneous insulin infusion (CSII) alone. Methods. 60 @entity1 with newly diagnosed T2DM were randomized into two groups (n = 30 each) and treated for 2 weeks with CSII alone (CSII group) or with CSII plus @entity12350 (CSII + Sig group). The glycemic variability of the @entity1 was measured using a continuous @entity413 monitoring system (CGMS) for the last 72 hours. A standard meal test was performed before and after the interventions, and the levels of glycated albumin, fasting @entity413 , fasting C-peptide, postprandial 2   h blood @entity413 , and postprandial 2   h C-peptide were examined. Results. Compared with the CSII group, the indicators of glycemic variability, such as the mean amplitude of glycemic excursion (MAGE) and the standard deviation of blood @entity413 (SDBG), were decreased significantly in the CSII + Sig group. The changes before and after treatment in the C-peptide reactivity index (  CPI) and the secretory unit of islet in transplantation index (  SUIT) indicated a significant improvement in the CSII + Sig group. Conclusions. Add-on therapy with @entity12350 may be an optimized treatment for @entity1 with newly diagnosed T2DM compared with short-term CSII alone.
